Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs PepsiCo, Inc. (PEP) Price & Performance

AbbVie IncTrade
PepsiCo, Inc.Trade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs PepsiCo, Inc. — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while PepsiCo, Inc. trades at $138.23 (market cap $187.99B). The key difference: AbbVie Inc is far larger — about 2.3× PepsiCo, Inc.'s market cap, and PepsiCo, Inc. pays the higher dividend (4.3%). Which is the better fit depends on your goals.

ABBVPEP
Market Cap
$438.19B$187.99B
Sector
HealthConsumer Staples
52-Week High
$263.58$170.44
52-Week Low
$197.38$134.95
Enterprise Value
$502.45B$230.48B
Dividend Yield
2.79%4.3%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

PepsiCo, Inc.

PepsiCo (PEP) trades at $137.69, down 0.95% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 10.78% net margin and 51.59% ROE, though Q3 2026 earnings are pending. Recent news highlights price adjustments on snack products and sponsorship changes, while analysts maintain a consensus Buy rating with $158.79 price target.

PEP offers steady dividend income and operational stability, but faces near-term pressure from consumer resistance to price hikes and competitive threats. The stock trades below consensus target with mixed technical indicators, presenting potential value for long-term investors willing to navigate current volatility and margin pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About PepsiCo, Inc.

PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.

Read more on PEP